BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 23582921)

  • 41. Multiple neuroendocrine tumors in the stomach, duodenum and pancreas of a MEN1 patient.
    Wang S; Zhang W; Xu M; Xia M
    Rev Esp Enferm Dig; 2024 Jun; 116(6):339-341. PubMed ID: 37350653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathology - grading and staging of GEP-NETs.
    Capelli P; Fassan M; Scarpa A
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):705-17. PubMed ID: 23582914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
    Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U
    Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
    Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
    Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.
    de Baere T; Deschamps F; Tselikas L; Ducreux M; Planchard D; Pearson E; Berdelou A; Leboulleux S; Elias D; Baudin E
    Eur J Endocrinol; 2015 Apr; 172(4):R151-66. PubMed ID: 25385817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
    Noor M; Huber AR; Cates JMM; Gonzalez RS
    Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
    Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
    J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery.
    Canellas R; Lo G; Bhowmik S; Ferrone C; Sahani D
    J Magn Reson Imaging; 2018 Feb; 47(2):425-432. PubMed ID: 28480609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Distal Predilection of Small Bowel Neuroendocrine Tumors.
    Keck KJ; Maxwell JE; Utria AF; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2018 Oct; 25(11):3207-3213. PubMed ID: 30054825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy].
    Fischer L; Mehrabi A; Büchler MW
    Chirurg; 2011 Jul; 82(7):583-90. PubMed ID: 21656305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
    Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
    Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).
    van Beek DJ; Nell S; Pieterman CRC; de Herder WW; van de Ven AC; Dekkers OM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Surg Oncol; 2019 Nov; 120(6):966-975. PubMed ID: 31401809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
    Singh S; Moody L; Chan DL; Metz DC; Strosberg J; Asmis T; Bailey DL; Bergsland E; Brendtro K; Carroll R; Cleary S; Kim M; Kong G; Law C; Lawrence B; McEwan A; McGregor C; Michael M; Pasieka J; Pavlakis N; Pommier R; Soulen M; Wyld D; Segelov E;
    JAMA Oncol; 2018 Nov; 4(11):1597-1604. PubMed ID: 30054622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imaging features of malignant abdominal neuroendocrine tumors with rare presentation.
    Corrias G; Monti S; Horvat N; Tang L; Basturk O; Saba L; Mannelli L
    Clin Imaging; 2018; 51():59-64. PubMed ID: 29448120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Letter to the Editor: Comment on 'Surgery as a Principle and Technical Consideration for Primary Tumor Resection of Small Bowel Neuroendocrine Tumors'.
    Kaçmaz E; Engelsman AF; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2024 May; 31(5):3265-3266. PubMed ID: 38478291
    [No Abstract]   [Full Text] [Related]  

  • 59. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.